A healthy 25-year-old man presents with a painless testicular mass. Ultrasound revealed a 5 cm solid mass, appearing to replace the left testicle. A left radical orchiectomy is performed.

Introduction: Robotic retroperitoneal lymph node dissection (RPLND) has emerged as a minimally invasive alternative for the management of testicular germ cell tumors, offering reduced morbidity and ...

To evaluate the feasibility and preliminary outcomes of prone retroperitoneal robotic-assisted laparoscopic pyeloplasty (prRALP) for ureteropelvic junction obstruction (UPJO), an innovative approach ...

Since the introduction of shockwave lithotripsy in 1980 for the management of renal stones, minimally invasive therapy for urolithiasis has improved and various new techniques have been introduced. [3 ...

TUESDAY, Nov. 5, 2024 (HealthDay News) — Open primary retroperitoneal lymph node dissection (RPLND) has an acceptable morbidity profile in men with testicular cancer, according to a study published ...

Introduction: Historically, therapeutic avenues for patients with clinical stage II seminoma germ cell tumors (SGCT) were confined to radiotherapy and chemotherapy. While survival rates with these ...

To evaluate the perioperative as well as early oncological outcomes of patients undergoing robotic retroperitoneal lymph node dissection for treatment of testicular cancer. We conducted a prospective ...

Single-stage retrocrural and retroperitoneal lymph node dissection for metastatic germ cell tumor: The University of Southern California experience. This is an ASCO Meeting Abstract from the 2024 ASCO ...

On the basis of National Comprehensive Cancer Network guidelines, clinical stage (CS) II seminoma is treated with radiotherapy or chemotherapy. Primary retroperitoneal lymph node dissection (RPLND) ...

To compare the perioperative outcomes of L-RPLND, R-RPLND and O-RPLND, and determine which one can be the mainstream option. We retrospectively reviewed medical records of 47 patients undergoing ...

First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401 Patients who underwent ...